Supplementary File

Circulation Journal
Official Journal of the Japanese Circulation Society
http://www. j-circ.or.jp

Circ J 2014; 78: 25122515

Differences Between Rosuvastatin and

Atorvastatin in Lipid-Lowering Action and Effect on
Glucose Metabolism in Japanese Hypercholesterolemic
Patients With Concurrent Diabetes
Lipid-Lowering With Highly Potent Statins in Hyperlipidemia With
Type 2 Diabetes Patients (LISTEN) Study
Hisao Ogawa, MD, PhD; Kunihiko Matsui, MD, PhD; Yoshihiko Saito, MD, PhD;
Seigo Sugiyama, MD, PhD; Hideaki Jinnouchi, MD, PhD; Masahiro Sugawara, MD, PhD;
Izuru Masuda, MD, PhD; Hisao Mori, MD, PhD; Masako Waki, MD, PhD;
Minoru Yoshiyama, MD, PhD; Hirotaka Watada, MD, PhD

Supplementary File 1
TableS1. Baseline Characteristics of Subjects in the LISTEN Study

Male (%)
Age (years)
BMI
Statin administration before starting the study (%)
Medical history (%)
Cardiovascular/cerebrovascular events
Myocardial infarction
Angina pectoris
Heart failure
Revascularization
Cardiac arrhythmias
Cerebral hemorrhage
Cerebral infarction
Transient ischemic attack
Complications
Diabetic complications
Diabetic retinopathy
Diabetic nephropathy
Diabetic neuropathy
Hypertension*
Lipid parameters
Non-HDL-C (mg/dl)
TC (mg/dl)
LDL-C (mg/dl)
HDL-C (mg/dl)
LDL-C/HDL-C ratio
Non-HDL-C/HDL-C ratio
TG (mg/dl)
FFA (mEq/L)
Parameters related to glucose level
HbA1c (NGSP value) (%)
Blood glucose (mg/dl)
Insulin (U/ml)
1,5-AG (g/ml)
HOMA-IR

All subjects
(n=1,018)

Rosuvastatin
(n=514)

Atorvastatin
(n=504)

466 (45.8)
66.411.1
25.354.09
241 (23.7)

235 (45.7)
66.311.6
25.504.04
121 (23.5)

231 (45.8)
66.610.6
25.194.15
120 (23.8)

206 (20.2)
14 (1.4)
62 (6.1)
18 (1.8)
12 (1.2)
57 (5.6)
9 (0.9)
51 (5.0)
9 (0.9)

103 (20.0)
7 (1.4)
31 (6.0)
8 (1.6)
9 (1.8)
26 (5.1)
6 (1.2)
30 (5.8)
4 (0.8)

103 (20.4)
7 (1.4)
31 (6.2)
10 (2.0)
3 (0.6)
31 (6.2)
3 (0.6)
21 (4.2)
5 (1.0)

0.88

116 (11.4)
13 (1.3)
34 (3.3)
46 (4.5)
645 (63.4)

67 (13.0)
9 (1.8)
21 (4.1)
23 (4.5)
338 (65.8)

49 (9.7)
4 (0.8)
13 (2.6)
23 (4.6)
307 (60.9)

0.11
0.26
0.22

168.933.3
223.934.0
139.430.0
54.914.1
2.690.86
3.301.20
152.1115.8
0.5840.298

168.935.8
223.036.0
139.231.9
54.113.6
2.730.91
3.361.31
154.5137.1
0.5840.299

169.030.6
224.831.8
139.627.9
55.814.6
2.660.81
3.251.07
149.689.1
0.5850.297

0.41
0.15
0.45
0.08
0.36
0.43
0.73
0.91

6.390.63

6.400.66
119.131.2
12.5720.07
15.398.10
3.936.32

6.380.59
118.827.0**
10.9518.66**
15.407.91**

0.80
0.54
0.13
0.97
0.19

118.929.2**
11.7719.39**
15.408.01**

3.696.97

3.447.58

P value
>0.99
0.99
0.24
0.94

>0.99
>0.99
0.64
0.14
0.50
0.51
0.25
0.75

>0.99
0.12

Data given as meanSD or n (%).

*Documented complication or documented use of concomitant medications for treatment of hypertension.
**One subject excluded from analysis because of protocol violation of prohibited therapy received before enrolment.
CI, confidential interval; FFA, free fatty acid; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LISTEN,
LIpid-lowering with highly potent Statins in hyperlipidemia with Type 2 diabetes patiENts; SD, standard deviation; TC, total cholesterol; TG,
triglyceride.
Circulation Journal Vol.78,October2014

TableS2. Change in Therapy for DM Among Subjects of the LISTEN Study

Rosuvastatin
(n=514)

Atorvastatin
(n=504)

P value
0.04

Change in DM therapy (%)

61 (11.9)

83 (16.5)

Addition of new drug

29 (5.6)

54 (10.7)

Gliclazide

0 (0.0)

2 (0.4)

Glimepiride

4 (0.8)

4 (0.8)

Metformin hydrochloride

11 (2.1)

7 (1.4)

Pioglitazone hydrochloride

2 (0.4)

2 (0.4)

Sitagliptin phosphate hydrate

6 (1.2)

14 (2.8)

Alogliptin benzoate

4 (0.8)

7 (1.4)

Vildagliptin

3 (0.6)

10 (2.0)

Linagliptin

0 (0.0)

3 (0.6)

Teneligliptin hydrobromide hydrate

0 (0.0)

1 (0.2)

Voglibose

0 (0.0)

2 (0.4)

Miglitol

0 (0.0)

3 (0.6)

Mitiglinide calcium hydrate

0 (0.0)

1 (0.2)

Liraglutide

1 (0.2)

0 (0.0)

Insulin glargine

0 (0.0)

2 (0.4)

Increased dosage

15 (2.9)

10 (2.0)

Gliclazide

0 (0.0)

1 (0.2)

Glimepiride

7 (1.4)

3 (0.6)

Metformin hydrochloride

5 (1.0)

4 (0.8)

Pioglitazone hydrochloride

1 (0.2)

0 (0.0)

Sitagliptin phosphate hydrate

3 (0.6)

2 (0.4)

Vildagliptin

1 (0.2)

0 (0.0)

Drug changes (judged as therapy intensification)

1 (0.2)

0 (0.0)

DPP4 inhibitor change+metformin hydrochloride

1 (0.2)

0 (0.0)

Subtotal of therapy intensification (%)

45 (8.8)

64 (12.7)

Drug changes (other than the above)

4 (0.8)

8 (1.6)

Decrease of medication

5 (1.0)

6 (1.2)

Finishing medication

7 (1.4)

5 (1.0)

03 months

14 (2.7)

20 (4.0)

36 months

8 (1.6)

12 (2.4)

612 months

23 (4.5)

32 (6.3)

03 months

5 (1.0)

6 (1.2)

36 months

5 (1.0)

5 (1.0)

612 months

6 (1.2)

8 (1.6)

Change in timing after first dose of statins (%)

Therapy intensification

Other than the above

DM, diabetes mellitus. Other abbreviations as in Table S1.

Circulation Journal Vol.78,October2014

0.04

FigureS1.Analyses performed using repeated measures ANOVA for overall comparison between treatment groups. The unpaired
t-test adjusted by Holms method was used for intergroup comparison to avoid multiplicity at multiple time points. LDL-C, lowdensity lipoprotein cholesterol; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.

Circulation Journal Vol.78,October2014

FigureS2.Analyses performed using repeated measures ANOVA for overall comparison between treatment groups. The unpaired
t-test adjusted by Holms method was used for intergroup comparison to avoid multiplicity at multiple time points.

Circulation Journal Vol.78,October2014